166 related articles for article (PubMed ID: 26342093)
1. Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.
van Herwaarden N; Bouman CA; van der Maas A; van Vollenhoven RF; Bijlsma JW; van den Hoogen FH; den Broeder AA; van den Bemt BJ
Ann Rheum Dis; 2015 Dec; 74(12):2260-1. PubMed ID: 26342093
[No Abstract] [Full Text] [Related]
2. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
[TBL] [Abstract][Full Text] [Related]
3. Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept.
Dervieux T; Kremer JM; Weinblatt ME
Ann Rheum Dis; 2019 Sep; 78(9):1285-1286. PubMed ID: 30885995
[No Abstract] [Full Text] [Related]
4. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
5. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
6. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2008 Aug; 24(8):2229-40. PubMed ID: 18577308
[TBL] [Abstract][Full Text] [Related]
7. Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population.
Fisher MD; Watson C; Fox KM; Chen YW; Gandra SR
Curr Med Res Opin; 2013 May; 29(5):561-8. PubMed ID: 23489410
[TBL] [Abstract][Full Text] [Related]
8. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
9. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
van Dartel SA; Fransen J; Kievit W; Flendrie M; den Broeder AA; Visser H; Hartkamp A; van de Laar MA; van Riel PL
Ann Rheum Dis; 2013 Jun; 72(6):895-900. PubMed ID: 22887849
[TBL] [Abstract][Full Text] [Related]
10. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
[TBL] [Abstract][Full Text] [Related]
11. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
[TBL] [Abstract][Full Text] [Related]
14. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
15. Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis.
Santoleri F; Sorice P; Lasala R; Rizzo RC; Costantini A
J Med Econ; 2014 May; 17(5):320-5. PubMed ID: 24641160
[TBL] [Abstract][Full Text] [Related]
16. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
17. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
[TBL] [Abstract][Full Text] [Related]
18. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study.
Schabert VF; Bruce B; Ferrufino CF; Globe DR; Harrison DJ; Lingala B; Fries JF
Curr Med Res Opin; 2012 Apr; 28(4):569-80. PubMed ID: 22236091
[TBL] [Abstract][Full Text] [Related]
19. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice.
Huang X; Gu NY; Fox KM; Harrison DJ; Globe D
Curr Med Res Opin; 2010 Jul; 26(7):1637-45. PubMed ID: 20429830
[TBL] [Abstract][Full Text] [Related]
20. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]